benzydamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
3881 642-72-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • benzydamine HCl
  • benzydamine hydrochloride
  • benzydamide
  • benzydamine
  • benzidamine
  • benzindamine
A benzyl-indazole having analgesic, antipyretic, and anti-inflammatory effects. It is used to reduce post-surgical and post-traumatic pain and edema and to promote healing. It is also used topically in treatment of RHEUMATIC DISEASES and INFLAMMATION of the mouth and throat.
  • Molecular weight: 309.41
  • Formula: C19H23N3O
  • CLOGP: 4.29
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 0
  • TPSA: 30.29
  • ALOGS: -3.80
  • ROTB: 7

Drug dosage:

DoseUnitRoute
0.15 g O
0.15 g R
9 mg O

ADMET properties:

PropertyValueReference
BA (Bioavailability) 87 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.53 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.28 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.80 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 8.10 hours Lombardo F, Berellini G, Obach RS

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Mouth ulceration 131.45 35.58 53 3016 27971 50574084
Skin candida 118.67 35.58 25 3044 1301 50600754
Neutropenic sepsis 107.13 35.58 38 3031 14109 50587946
Hypomagnesaemia 88.95 35.58 38 3031 23118 50578937
Mucosal inflammation 83.18 35.58 43 3026 40099 50561956
Diarrhoea 80.58 35.58 134 2935 588342 50013713
Constipation 58.91 35.58 64 3005 185644 50416411
Intestinal dilatation 56.93 35.58 14 3055 1454 50600601
Nervous system disorder 47.42 35.58 22 3047 16201 50585854
Nausea 46.49 35.58 119 2950 705279 49896776
Hypokalaemia 46.11 35.58 40 3029 87952 50514103
Vomiting 45.04 35.58 91 2978 460667 50141388
Rhinovirus infection 44.76 35.58 14 3055 3520 50598535
Macular degeneration 40.46 35.58 19 3050 14369 50587686
Decreased appetite 40.38 35.58 55 3014 200868 50401187

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neutropenic sepsis 46.85 35.74 16 802 11711 29561998

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Mouth ulceration 148.09 33.67 60 3809 32384 64462479
Neutropenic sepsis 141.49 33.67 53 3816 23219 64471644
Skin candida 107.20 33.67 24 3845 1679 64493184
Diarrhoea 77.27 33.67 147 3722 722557 63772306
Hypomagnesaemia 71.96 33.67 38 3831 37338 64457525
Mucosal inflammation 68.26 33.67 44 3825 62540 64432323
Constipation 61.37 33.67 72 3797 229265 64265598
Intestinal dilatation 51.06 33.67 14 3855 2250 64492613
Hypokalaemia 47.96 33.67 47 3822 121856 64373007
Nausea 44.84 33.67 125 3744 785675 63709188
Bleeding time prolonged 44.54 33.67 11 3858 1175 64493688
Vomiting 41.01 33.67 97 3772 551020 63943843
Nervous system disorder 37.54 33.67 21 3848 23057 64471806
Rhinovirus infection 33.69 33.67 13 3856 6143 64488720

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A01AD02 ALIMENTARY TRACT AND METABOLISM
STOMATOLOGICAL PREPARATIONS
STOMATOLOGICAL PREPARATIONS
Other agents for local oral treatment
ATC G02CC03 GENITO URINARY SYSTEM AND SEX HORMONES
OTHER GYNECOLOGICALS
OTHER GYNECOLOGICALS
Antiinflammatory products for vaginal administration
ATC M01AX07 MUSCULO-SKELETAL SYSTEM
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
Other antiinflammatory and antirheumatic agents, non-steroids
ATC M02AA05 MUSCULO-SKELETAL SYSTEM
TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
Antiinflammatory preparations, non-steroids for topical use
ATC R02AX03 RESPIRATORY SYSTEM
THROAT PREPARATIONS
THROAT PREPARATIONS
Other throat preparations
MeSH PA D000893 Anti-Inflammatory Agents
CHEBI has role CHEBI:35337 analeptic
CHEBI has role CHEBI:35475 non-steroidal anti-inflammatory agent
CHEBI has role CHEBI:35499 hallucinogens
CHEBI has role CHEBI:36333 local anesthetics

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Pain indication 22253000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.78 Basic
pKa2 1.65 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Soluble guanylate cyclase Enzyme EC50 5.99 CHEMBL

External reference:

IDSource
D01410 KEGG_DRUG
132-69-4 SECONDARY_CAS_RN
C0005099 UMLSCUI
CHEBI:94563 CHEBI
CHEMBL12610 ChEMBL_ID
CHEMBL1528134 ChEMBL_ID
D001591 MESH_DESCRIPTOR_UI
DB09084 DRUGBANK_ID
1927 INN_ID
4O21U048EF UNII
12555 PUBCHEM_CID
1425 RXNORM
003474 NDDF
004658 NDDF
331143003 SNOMEDCT_US
350307000 SNOMEDCT_US
421319000 SNOMEDCT_US

Pharmaceutical products:

None